Metropolitan Life Insurance Co. NY Holds Stake in Xencor, Inc. (XNCR)

Metropolitan Life Insurance Co. NY continued to hold its position in shares of Xencor, Inc. (NASDAQ:XNCR) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,914 shares of the biopharmaceutical company’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY owned approximately 0.05% of Xencor worth $596,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of XNCR. Redmile Group LLC boosted its stake in Xencor by 59.9% in the first quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock worth $38,093,000 after buying an additional 596,426 shares during the period. AQR Capital Management LLC boosted its stake in Xencor by 27.7% in the first quarter. AQR Capital Management LLC now owns 188,743 shares of the biopharmaceutical company’s stock worth $4,515,000 after buying an additional 40,906 shares during the period. Gotham Asset Management LLC boosted its stake in Xencor by 1.9% in the first quarter. Gotham Asset Management LLC now owns 253,153 shares of the biopharmaceutical company’s stock worth $6,055,000 after buying an additional 4,778 shares during the period. State Street Corp boosted its stake in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock worth $23,751,000 after buying an additional 148,136 shares during the period. Finally, Bank of America Corp DE boosted its stake in Xencor by 144.4% in the first quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 9,572 shares during the period. 73.53% of the stock is currently owned by hedge funds and other institutional investors.

Xencor, Inc. (XNCR) traded down 2.01% on Friday, hitting $19.94. 202,717 shares of the company were exchanged. The firm’s market cap is $935.70 million. Xencor, Inc. has a one year low of $18.45 and a one year high of $29.38. The stock has a 50 day moving average price of $22.56 and a 200 day moving average price of $23.00.

Xencor (NASDAQ:XNCR) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. On average, equities research analysts forecast that Xencor, Inc. will post ($1.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Metropolitan Life Insurance Co. NY Holds Stake in Xencor, Inc. (XNCR)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/metropolitan-life-insurance-co-ny-continues-to-hold-stake-in-xencor-inc-xncr-updated.html.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a report on Saturday, April 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 price target on shares of Xencor in a report on Tuesday, August 8th. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $29.00 price target on shares of Xencor in a report on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Xencor presently has an average rating of “Hold” and a consensus target price of $29.33.

In related news, major shareholder John S. Stafford III bought 1,500 shares of Xencor stock in a transaction dated Friday, June 16th. The shares were bought at an average cost of $19.67 per share, for a total transaction of $29,505.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder John S. Stafford III bought 6,000 shares of Xencor stock in a transaction dated Wednesday, June 28th. The shares were bought at an average price of $19.94 per share, for a total transaction of $119,640.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 182,035 shares of company stock worth $3,728,456 and have sold 34,766 shares worth $739,408. 4.03% of the stock is currently owned by corporate insiders.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

What are top analysts saying about Xencor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xencor Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit